BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Deloitte
Merck
Novartis
UBS
Fish and Richardson
Teva
Dow
Express Scripts
Colorcon

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,636,001

« Back to Dashboard

Summary for Patent: 8,636,001
Title:Dry powder inhaler and system for drug delivery
Abstract: A breath-powered, dry powder inhaler, a cartridge, and a pulmonary drug delivery system are provided. The dry powder inhaler can be provided with or without a unit dose cartridge for using with the inhaler. The inhaler and/or cartridge can be provided with a drug delivery formulation comprising, for example, a diketopiperazine and an active ingredient, including, peptides and proteins such as insulin and glucagon-like peptide 1 for the treatment of diabetes and/or obesity. The dry powder inhaler is compact; can be provided in various shapes and sizes, colors, and comprises a housing, a mouthpiece, a cartridge placement area, and a mechanism for opening and closing the medicament cartridge. The device is easy to manufacture, provides a pre-metered single unit dose, it is relatively easy to use, and can be reusable or disposable.
Inventor(s): Smutney; Chad C. (Watertown, CT), Kinsey; P. Spencer (Sandy Hook, CT), Sahi; Carl R. (Coventry, CT), Adamo; Benoit (Mount Kisco, NY), Polidoro; John M. (Coventry, CT), McLean; Scott (Waterbury, CT), Overfileld; Dennis (Fairfield, CT), Bryant; Anthony (Stratford, CT), He; Tom (Valencia, CA), Mann; Alfred (Valencia, CA)
Assignee: Mannkind Corporation (Valencia, CA)
Application Number:12/484,129
Patent Claim Types:
see list of patent claims
Delivery; Use;

Drugs Protected by US Patent 8,636,001

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-001 Jun 27, 2014 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-002 Jun 27, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Mannkind AFREZZA insulin recombinant human POWDER;INHALATION 022472-003 Apr 17, 2015 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,636,001

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,420,604 Method of drug formulation of compositions comprising crystalline microparticle surfaces ➤ Subscribe
8,912,193 Dry powder inhaler and system for drug delivery ➤ Subscribe
9,358,352 Dry powder drug delivery system and methods ➤ Subscribe
7,799,344 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents ➤ Subscribe
9,446,133 Dry powder inhaler and system for drug delivery ➤ Subscribe
9,393,372 Dry powder drug delivery system ➤ Subscribe
8,499,757 Dry powder inhaler and system for drug delivery ➤ Subscribe
9,089,497 Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces ➤ Subscribe
9,078,866 Method for treating hyperglycemia with GLP-1 ➤ Subscribe
8,921,311 Method for treating hyperglycemia ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,636,001

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 101969928 ➤ Subscribe
Brazil PI0615819 ➤ Subscribe
Brazil PI0616071 ➤ Subscribe
Brazil PI0709964 ➤ Subscribe
Brazil PI0818872 ➤ Subscribe
Brazil PI0818874 ➤ Subscribe
Canada 2493478 ➤ Subscribe
Canada 2620758 ➤ Subscribe
Canada 2621806 ➤ Subscribe
China 102614131 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Dow
QuintilesIMS
US Department of Justice
Novartis
Citi
Merck
Chubb
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot